Robert E. Slayton

1.1k total citations
37 papers, 802 citations indexed

About

Robert E. Slayton is a scholar working on Surgery, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert E. Slayton has authored 37 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 10 papers in Reproductive Medicine and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert E. Slayton's work include Testicular diseases and treatments (12 papers), Ovarian cancer diagnosis and treatment (10 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Robert E. Slayton is often cited by papers focused on Testicular diseases and treatments (12 papers), Ovarian cancer diagnosis and treatment (10 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Robert E. Slayton collaborates with scholars based in United States and Singapore. Robert E. Slayton's co-authors include Charles P. Perlia, Arthur H. Rossof, John A. Blessing, Steven G. Silverberg, Hugh M. Shingleton, Philip Bonomi, William T. Creasman, Robert C. Park, Paul Elson and Janet Wolter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Robert E. Slayton

36 papers receiving 712 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. Slayton United States 13 357 222 213 193 130 37 802
C. P. J. Vendrik Netherlands 12 358 1.0× 148 0.7× 342 1.6× 234 1.2× 213 1.6× 26 758
B Kabakow United States 15 208 0.6× 331 1.5× 243 1.1× 88 0.5× 91 0.7× 47 734
J Chauvergne France 16 219 0.6× 132 0.6× 353 1.7× 208 1.1× 121 0.9× 107 833
S. J. Harland United Kingdom 18 410 1.1× 172 0.8× 390 1.8× 219 1.1× 398 3.1× 32 1.1k
Dianne M. Howser United States 9 128 0.4× 135 0.6× 175 0.8× 64 0.3× 64 0.5× 12 491
Martine George United States 9 106 0.3× 146 0.7× 277 1.3× 298 1.5× 120 0.9× 16 898
Engracio P. Cortes United States 13 194 0.5× 40 0.2× 439 2.1× 372 1.9× 120 0.9× 22 901
E. Sandberg Denmark 10 221 0.6× 205 0.9× 382 1.8× 163 0.8× 60 0.5× 17 749
P. Dohrmann Germany 14 193 0.5× 50 0.2× 185 0.9× 301 1.6× 182 1.4× 46 761
D A Hall United States 16 164 0.5× 174 0.8× 110 0.5× 141 0.7× 100 0.8× 23 671

Countries citing papers authored by Robert E. Slayton

Since Specialization
Citations

This map shows the geographic impact of Robert E. Slayton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Slayton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Slayton more than expected).

Fields of papers citing papers by Robert E. Slayton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Slayton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Slayton. The network helps show where Robert E. Slayton may publish in the future.

Co-authorship network of co-authors of Robert E. Slayton

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Slayton. A scholar is included among the top collaborators of Robert E. Slayton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Slayton. Robert E. Slayton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Slayton, Robert E., John A. Blessing, & Daniel L. Clarke‐Pearson. (1991). A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. Investigational New Drugs. 9(1). 93–94. 5 indexed citations
2.
Slayton, Robert E., John A. Blessing, Katherine Y. Look, & Barrie Anderson. (1991). A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. Investigational New Drugs. 9(2). 207–208. 17 indexed citations
3.
Slayton, Robert E., John A. Blessing, Mark A. Rettenmaier, & Harrison Ball. (1989). A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix. Investigational New Drugs. 7(4). 337–340. 5 indexed citations
4.
Williams, Shanna, John A. Blessing, Robert E. Slayton, Howard D. Homesley, & Guy J. Photopulos. (1989). Ovarian germ cell tumors: Adjuvant trials of the Gynecologic Oncology Group (GOG). Gynecologic Oncology. 32(1). 124–124. 12 indexed citations
5.
Slayton, Robert E., et al.. (1988). A Phase II Clinical Trial of Diaziquone in the Treatment of Patients with Recurrent Endometrial Carcinoma. American Journal of Clinical Oncology. 11(6). 612–613. 6 indexed citations
6.
Slayton, Robert E., et al.. (1988). Primary retroperitoneal pure choriocarcinoma. Two long-term complete responders from a rare fatal disease. Cancer. 62(6). 1053–1054. 9 indexed citations
7.
Roth, Lawrence M., Robert E. Slayton, Luther W. Brady, John A. Blessing, & Gary D. Johnson. (1985). Retiform differentiation in ovarian sertoli-leydig cell tumors. A clinicopathologic study of six cases from a gynecologic oncology group study. Cancer. 55(5). 1093–1098. 20 indexed citations
8.
9.
Slayton, Robert E., Robert C. Park, Steven G. Silverberg, et al.. (1985). Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A gynecologic oncology group study (a final report). Cancer. 56(2). 243–248. 111 indexed citations
10.
Bonomi, Philip, et al.. (1984). Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.. PubMed. 68(9). 1163–5. 11 indexed citations
11.
Earhart, Robert H., Paul Elson, Susan N. Rosenthal, Richard G. Hahn, & Robert E. Slayton. (1983). Phase II study of PALA and AMSA in advanced renal cell carcinoma. American Journal of Clinical Oncology. 6(5). 555–560. 10 indexed citations
12.
Slayton, Robert E.. (1982). New agents in ovarian cancer. International Journal of Radiation Oncology*Biology*Physics. 8(8). 1431–1434. 2 indexed citations
13.
Pazdur, Richard, Philip Bonomi, Robert E. Slayton, et al.. (1981). Neuroendocrine carcinoma of the cervix: Implications for staging and therapy. Gynecologic Oncology. 12(1). 120–128. 52 indexed citations
14.
Begg, Colin B., et al.. (1980). Chemotherapy for advanced germinal cell neoplasms: preliminary report of an Eastern Cooperative Oncology Group Study.. PubMed. 63(9-10). 1675–80. 8 indexed citations
15.
Slayton, Robert E., et al.. (1979). Treatment of Malignant Ovarian Germ Cell Tumors Response to Vincristine, Dactinomycin, and Cyclophosphamide (Preliminary Report). Obstetrical & Gynecological Survey. 34(1). 67–69. 1 indexed citations
16.
Slayton, Robert E., M.M. Hreshchyshyn, Steven G. Silverberg, et al.. (1978). Treatment of malignant ovarian germ cell tumors.Response to vincristine, dactinomycin, and cyclophosphamide (preliminary report). Cancer. 42(2). 390–398. 70 indexed citations
17.
Bonomi, Philip, Robert E. Slayton, & J Wolter. (1978). Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.. PubMed. 62(8). 1211–3. 11 indexed citations
18.
Slayton, Robert E., et al.. (1973). Combination chemotherapy with bleomycin and methotrexate in recurrent and disseminated cervical carcinoma: A preliminary study. Gynecologic Oncology. 1(2). 184–190. 9 indexed citations
19.
Slayton, Robert E., et al.. (1971). Clinical study with bleomycin. Cancer. 28(5). 1142–1146. 59 indexed citations
20.
Slayton, Robert E., et al.. (1955). Lente Insulin in the Treatment of Diabetes. New England Journal of Medicine. 253(17). 722–725. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. P. J. Vendrik Breakdown of academic impact, for papers by B Kabakow Breakdown of academic impact, for papers by J Chauvergne Breakdown of academic impact, for papers by S. J. Harland Breakdown of academic impact, for papers by Dianne M. Howser Breakdown of academic impact, for papers by Martine George Breakdown of academic impact, for papers by Engracio P. Cortes Breakdown of academic impact, for papers by E. Sandberg Breakdown of academic impact, for papers by P. Dohrmann Breakdown of academic impact, for papers by D A Hall
Rankless by CCL
2026